FM is a disease process characterized by chronic widespread musculoskeletal pain, non-restorative sleep, fatigue, headache, morning stiffness, poor memory, difficulty concentrating, paresthesias (numbness and tingling) and overall impaired functioning in both social and occupational settings.[1,3,15,16] The severity of the pain is typically more constant than other forms of pain and may come and go rapidly, move around to various parts of the body, and worsen with touch. For example, some fibromyalgia patients find their own clothing against their skin painful, particularly if it is tight clothing.
Fibromyalgia is the 2nd most common disorder seen by rheumatologists, affecting roughly 2% of the population of the United States and 1.4% of the population of France.[1,4,12] Middle aged women are afflicted at a higher rate, with a prevalence of 3.4% for women, and 0.5% for men.[1,4] An Iceland study estimates the prevalence of children affected by fibromyalgia at 1.2% - 6.2%.
Prevalence increases with age and diagnosis is most common in people aged 60 and 79 years. Prevalence is higher in families, with relatives of patients suffering from fibromyalgia having an 8.5 fold higher risk of developing the disease.[2,5,6,7] Family members are also more likely to have other pain syndromes and tender points when compared to non-family members, suggesting an environmental or genetic component.
Kato and colleagues used structural equation modeling to support the role of genetic factors, thus determining that these influences have a modest impact which explains 50% of the total variance in the likelihood of developing chronic widespread pain.[2,11] However, there is no particular gene that has been identified that leads to the disease.[2,11]
The diagnosis of fibromyalgia is made by specific criteria from the American College of Rheumatology (ACR) after other potentially causative systemic conditions have been ruled out. A thorough physical and neurological exam with thyroid function testing is generally conducted before fibromyalgia is considered.[15,16]
The diagnosis [15,16] can be made with the presence of widespread pain for a period of at least three months, and either:
1. The presence pain at 11 of 18 tender point sites,
2. Or, the presence of at least 4 of the following:
· Generalized Fatigue
· Sleep Disturbance
· Neuropsychiatric Complaints
· Numbness and/or Tingling
· Irritable Bowel Syndrome
There are specific conditions which are frequently comorbid (occurring simultaneously) with fibromyalgia, including osteoarthritis, autoimmune disease, lupus, myalgic encephalomyelitis / chronic fatigue syndrome, migraines, irritable bowel syndrome, sleep problems, mood disturbances, nueroendocrine disorders, and hypothyroidism.[11,17] Bennett and colleagues conducted survey which showed the following prevalence of comorbid disorders:[3,9]
Low back pain 63%
Recurrent headaches 47%
Muscle spasm 46%
Balance problems 45%
Irritable bowel syndrome 44%
Chronic fatigue 40%
Sinus problems 37%
Tooth disorders 32%
Restless legs 32%
Jaw pain 29%
Bladder problems 26%
Upon examination, no structural changes or muscular inflammation is detectable despite a widespread decreased pain threshold and peripheral sensitization indicative of changes in pain pathways with elevated cerebrospinal substance P levels and dysfunction of the hypothalamic pituitary adrenal (HPA) axis.[11,17,22,23]
The cause of fibromyalgia is not fully understood yet, though it may involve abnormalities in peripheral and central sensory processing, which may be triggered by viral infections, Lyme disease, hepatitis C, hormonal and endocrine changes, drugs, vaccines, and physical trauma.[8,17,18,19,20,21,24,25,26].
Nuclear medicine utilizes SPECT (Single Photon Emission Computerized Tomography) technology to perform brain scans. This records brain functioning by measuring perfusion (blood flow). In patients with fibromyalgia, cerebral blood flow is altered. Furthermore, the larger alternations in perfusion have been linked to increased symptom reports.  Significant hyperperfusion has been found in regions of the brain known to be involved in the sensory dimension of pain processing.
Gi protein is hypofunctional in fibromyalgia and unaltered in neuropathic pain, rheumatoid arthritis, and osteoarthritis. Furthermore, patients with fibromyalgia showed basal cAMP levels which were higher than the controls.
Reduced dopamine, norepinephrine, and serotonin levels have been found in the cerebrospinal fluid of fibromyalgia subjects. Dopamine is an important neurotransmitter (messenger) which facilitates critical brain functions. Imbalanced dopamine activity can cause brain dysfunction and disease. Classified as a catecholamine, dopamine improves nerve conduction, is a natural pain killer, and assists in lessening movement disorders such as that seen in Parkinson’s disease.
Various “stressors” such as viral infection, physical trauma, and exercise can both initiate and trigger fibromyalgia.[8,37] Illness or injury may damage the corticotropin-releasing hormone nervous system that activates the sympathetic nervous system and reduces cellular immune function.[8,37] In patients with fibromyalgia this system functions suboptimally, leading to increased physiologic response.[8,37]
There are several conditions which mimic fibromyalgia and should be ruled out and/or treated. They include hypothyroidism, polymyalgia rheumatica, autoimmune disorders, hepatitis C, sleep apnea, chiari malformation, and celiac disease. 
Medications alone are generally not effective for fibromyalgia.[1,45] A multidisciplinary approach is recommended by the American Pain Society Fibromyalgia Panel.[1,45]
Fibromyalgia may be treated using both conventional and alternative medicine to improve symptoms and generally involves patient education, exercise, physical therapy, supplementation, and pharmacologic therapy. Conventional medicine relies on pharmacological treatments to manage symptoms such as pain, fatigue, and sleep problems, while non-pharmacological treatments, such as exercise, may help with functional improvements.
Patients may also benefit from psychosocial support, education about the disease, support groups, improved sleep, a supportive family, pacing, adopting a healthy lifestyle, avoiding chemical exposures (fragrances, pesticides, etc), and avoiding cigarettes and alcohol.
Survey respondents rate the most effective treatment modalities as rest, heat, pain medications, antidepressants (for use other than depression), and hypnotics.
Some pharmacological treatments that doctors may prescribe include:
Analgesics may be prescribed to block glutamate and substance p for pain relief.
Low doses of antidepressant medications may be prescribed to improve sleep and reduce pain.[4,8,47] The beneficial effects of antidepressants in FM are independent of their antidepressant effects.[4,47] Tricyclic antidepressants are the most studied antidepressants which have been shown to improve the symptoms of pain, poor sleep, and fatigue in several randomized, controlled trials. An example of some antidepressants includes amitriptyline, paroxetine, citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline.[4,47]
SSRI’s and SSNI’s
Selective Serotonin Reuptake Inhibitors (SSRI’s) and/or Selective Norepinephrine Reuptake Inhibitors (SSNI’s) may be helpful to improve physical impairment and functioning, fatigue, pain and stiffness, and number of tender points.[8,45,47,48,49,50,51,52] An example some SSRI’s and SSNI’s include duloxetine, milnacipran, fluoxetine and sertraline appear to be the most effective.
Lidocaine / Hydrocortisone Injections
Lidocaine and/or hydrocortisone may be prescribed for persistent pain in one area.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
NSAIDs may be used in some cases to reduce inflammation, though they are not often helpful in pain reduction.
Gamma-aminobutyric acid (GABA) antiepileptic drugs are commonly used for treatment of chronic pain. Pregabalin is one gamma-aminobutyric acid (GABA) analog that is approved for the treatment of neuropathic pain and has been shown to be effective in the significant reduction of pain, sleep disturbances, fatigue, and quality of life. Gabapentin has also been used to treat chronic pain states.
Non-medication methods to relieve symptoms include regular sleep, regular stretching and exercise, hot compresses, gentle massage, and supplementation.[4,47] Low impact aerobic exercise has been shown effective at increasing functional capacity.[47,56]
Nutrition therapy with certain agents that down-regulate the nitric oxide and peroxynitrite (NO/ONOO-) cycle of biochemistry has also been recommended. The following agents have been predicted to be useful to down-regulate the NO/ONOO- cycle and reduce symptoms in clinical trials:
Different combinations of the above treatments may be tried to find the one that works best for each patient.
1. Chakrabarty S, Zoorob R. Fibromyalgia. Am Fam Physician. 2007 Jul 15;76(2):247-54.
2. Kato K, Sullivan PF, Evengard B, Pedersen NL. Importance of genetic influences on chronic widespread pain. Arthritis Rheum. 2006;54:1682-1686.
3. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007 Mar 9;8:27.
4. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995 Jan;38(1):19-28.
5. Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. Arthritris Rheum. 2004;50:944-952.
6. Buskila D, Neumann L, Hazanov I, Carmi R. Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum. 1996;26:605-611.
7. Buskila D, Neumann L. Genetics of fibromyalgia. Curr Pain Headache Rep. 2005;9:313-315.
8. Clauw DJ. Fibromyalgia. In: Loeser JD, Butler SH, Chapman CR, Turk DC, eds. Bonica's Management of Pain, 4th edition. Philadelphia, Pa: Lippincott Williams and Wilkins. 2008.
9. Kato K, Sullivan PF, Evengard B, Pedersen NL. Chronic widespread pain and its comorbidities: a population-based study. Arch Intern Med. 2006;166:1649-1654.
10. Kato K, Sullivan PF, Evengard B, Pedersen NL. Importance of genetic influences on chronic widespread pain. Arthritis Rheum. 2006;54:1682-1686.
11. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol. 2003;17:685-701.
12. Bannwarth B, Blotman F, Roué-Le Lay K, Caubère JP, André E, Taïeb C. Fibromyalgia syndrome in the general population of France: A prevalence study. 2008 Sep 24.
13. Baldursdóttir S.Joint Bone Spine. [Juvenile primary fibromyalgia syndrome--review]. Laeknabladid. 2008 Jun;94(6):463-72.
14. Gay J. Canaris, MD, MSPH; Neil R. Manowitz, PhD; Gilbert Mayor, MD; E. Chester Ridgway, MD. The Colorado Thyroid Disease Prevalence Study. Arch Intern Med. 2000;160:526-534.
15. Chakrabarty S, Zoorob R. Fibromyalgia. Am Fam Physician. 2007 Jul 15;76(2):247-54.
16. Katz RS, Wolfe F, Michaud K. Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum. 2006 Jan;54(1):169-76.
17. McBeth J, Silman AJ, Gupta A, Chiu YH, Ray D, Morriss R, Dickens C, King Y, Macfarlane GJ. Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain: findings of a population-based prospective cohort study. Arthritis Rheum. 2007 Jan;56(1):360-71.
18. Buskila D, Neumann L, Vaisberg G, Alkalay D, Wolfe F. Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury. Arthritis Rheum. 1997;40:446-452.
19. Al-Allaf AW. Work disability and health system utilization in patients with fibromyalgia syndrome. J Clin Rheumatol. 2007;13:199-201.
20. Harkness EF, Macfarlane GJ, Nahit ES, Silman AJ, McBeth J. Mechanical and psychosocial factors predict new onset shoulder pain: a prospective cohort study of newly employed workers. Occup Environ Med. 2003;60:850-857.
21. Harkness EF, Macfarlane GJ, Nahit E, Silman AJ, McBeth J. Mechanical injury and psychosocial factors in the work place predict the onset of widespread body pain: a two-year prospective study among cohorts of newly employed workers. Arthritis Rheum. 2004;50:1655-1664.
22. Simms RW, Roy SH, Hrovat M, et al. Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism. Arthritis Rheum. 1994;37:794-800.
23. Staud R, Rodriguez ME. Mechanisms of disease: pain in fibromyalgia syndrome. Nat Clin Pract Rheumatol. 2006;2:90-98.
24. Buchwald DS, Rea TD, Katon WJ, Russo JE, Ashley RL. Acute infectious mononucleosis: characteristics of patients who report failure to recover. Am J Med. 2000;109:531-537.
25. Treib J, Grauer MT, Haass A, Langenbach J, Holzer G, Woessner R. Chronic fatigue syndrome in patients with Lyme borreliosis. Eur Neurol. 2000;43:107-109.
26. Candy B, Chalder T, Cleare AJ, Wessely S, White PD, Hotopf M. Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review. Br J Gen Pract. 2002;52:844-851.
27. Granot M, Buskila D, Granovsky Y, Sprecher E, Neumann L, Yarnitsky D. Simultaneous recording of late and ultra-late pain evoked potentials in fibromyalgia. Clin Neurophysiol. 2001;112:1881-1887.
28. Staud R, Cannon RC, Mauderli AP, Robinson ME, Price DD, Vierck CJ. Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and subjects with fibromyalgia syndrome. Pain. 2003;102:87-95.
29. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35:550-556.
30. Malt EA, Olafsson S, Aakvaag A, Lund A, Ursin H. Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population-based controls. J Affect Disord. 2003;75:77-82.
31. Wood PB, Patterson JC II, Sunderland JJ, Tainter KH, Glabus MF, Lilien DL. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain. 2007;8:51-58.
32. Bourgoin S, Pohl M, Mauborgne A, et al. Monoaminergic control of the release of calcitonin gene-related peptide and substance P-like materials from rat spinal cord slices. Neuropharmacology. 1993;32:633-640.
33. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37:1593-1601.
34. Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum. 1997;40:1928-1939.
35. Lautenbacher S, Rollman GB, McCain GA. Multi-method assessment of experimental and clinical pain in patients with fibromyalgia. Pain. 1994;59:45-53.
36. Sorensen J, Graven-Nielsen T, Henriksson KG, Bengtsson M, Arendt-Nielsen L. Hyperexcitability in fibromyalgia. J Rheumatol. 1998;25:152-155.
37. Sapolsky RM. Why stress is bad for your brain. Science. 1996;273:749-750.
38. Galeotti N, Ghelardini C, Zoppi M, Del Bene E, Raimondi L, Beneforti E, Bartolini A. A reduced functionality of Gi proteins as a possible cause of fibromyalgia. Journal of rheumatology. 2001;28(10);2298-2304.
39. Guedj E, Cammilleri S, Niboyet J, Dupont P, Vidal E, Dropinski JP, Mundler O. Clinical Correlate of Brain SPECT Perfusion Abnormalities in Fibromyalgia. J Nucl Med. 2008 Oct 16. [Epub ahead of print]
40. Guedj E, Taieb D, Cammilleri S, Lussato D, de Laforte C, Niboyet J, Mundler O.. 99mTc-ECD brain perfusion SPECT in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):130-4. Epub 2006 Aug 25.
41. Guedj E, Cammilleri S, Colavolpe C, de Laforte C, Niboyet J, Mundler O. Follow-up of pain processing recovery after ketamine in hyperalgesic fibromyalgia patients using brain perfusion ECD-SPECT. Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):2115-9. Epub 2007 Sep 21.
42. Gur A, Karakoc M, Erdogan S, Nas K, Cevik R, Sarac AJ. Regional cerebral blood flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol. 2002 Nov-Dec;20(6):753-60.
43. Sendur OF, Turan Y, Tastaban E, Yenisey C, Serter M. Serum antioxidants and nitric oxide levels in fibromyalgia: a controlled study. Rheumatol Int. 2008 Oct 14. [Epub ahead of print]
44. Buskila D.Genetics of chronic pain states. Best Pract Res Clin Rheumatol. 2007 Jun;21(3):535-47.
45. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292:2388-2395.
46. Simon, LS. Differential Diagnosis and Management of Fibromyalgia Syndrome. Medscape. 2008.
47. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics. 2000 Mar-Apr;41(2):104-13.
48. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol. 1994;23(5):255-9.
49. Nørregaard J, Volkmann H, Danneskiold-Samsøe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995 Jun;61(3):445-9.
50. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study. Eur J Pain. 2000;4(1):27-35.
51. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19(suppl 1):S27-S35.
52. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974-2984.
53. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2000;(3):CD001133.
54. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264-1273.
55. Redillas C, Solomon S. Prophylactic pharmacological treatment of chronic daily headache. Headache. 2000;40:83-102.
56. Busch AJ, Barber KA, Overend TJ, Peloso PM, Schachter CL. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev. 2007:CD003786.
57. Pall ML. Explaining “Unexplained Illnesses”: Disease Paradigm for Chronic Fatigue Syndrome, Multiple Chemical Sensitivity, Fibromyalgia, Post-Traumatic Stress Disorder, Gulf War Syndrome and Others. Hawthorn Medical Press. 2007.
This site is for informational purposes and is not intended to replace the examination, diagnosis and treatment of a licensed physician and no such claims are inferred. MCS America will not be responsible for misuse of this information or the misuse of any information provided by it’s member organizations. Articles, citations, links and information are not necessarily the opinion of MCS America and printing does not constitute endorsement.
"An illness is like a journey into a far country; it sifts all one's experience and removes it to a point so remote that it appears like a vision." Sholem Asch
Science & Medicine